Skip to main content
SpringerLink
Log in

Oral Faropenem Sodium — Implications for Antimicrobial Resistance and Treatment Effectiveness

  • Special Article
  • Published:
Indian Pediatrics Aims and scope Submit manuscript

Abstract

Rising antimicrobial resistance (AMR) is causing therapeutic failures with antibiotics. Inappropriate use is a contributing factor. One such antibiotic on the radar is faropenem, a broad spectrum antibiotic approved in 2005 in India. Recently, faropenem sodium suspension was approved for use in children. There is a potential danger of overuse due to the convenience of oral administration. Other carbapenems such as meropenem are used parenterally. Overuse of faropenem may promote cross-resistance with other carbapenems making them ineffective.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Dharmapalan D, Shet A, Yewale V, Sharland M. High reported rates of antimicrobial resistance in Indian Neonatal and Pediatric Blood Stream Infections. J Pediatric Infect Dis Soc. 2017; 6:e62–e68.

    Article  Google Scholar 

  2. World Health Organisation. Antiicrobial resistance. Accessed April 25, 2022. Available from: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance

  3. ICMR. Treatment Guidelines for Antimicrobial Use in Common Syndromes. Accessed May 05, 2022. Available from: https://main.icmr.nic.in/sites/default/files/guidelines/Treatment_Guidelines_2019_Final.pdf

  4. World Health Organisation. The WHO Essential Medicines List Antibiotic Book: improving antibiotic AWaReness. Updated 1 Feb 2022. Accessed May 24, 2022. Available from: https://www.who.int/publications/m/item/the-who-essential-medicines-list-antibiotic-book-improving-antibiotic-awarenessWHO.

  5. Gandra S, Choi J, McElvania E, et al. Faropenem resistance causes in vitro cross-resistance to carbapenems in ESBL-producing Escherichia coli. Int J Antimicrob Agents. 2020;55:105902.

    Article  CAS  Google Scholar 

  6. Schurek KN, Wiebe R, Karlowsky JA, et al. Faropenem: review of a new oral penem. Expert Rev Anti Infect Ther. 2007;5: 185–98.

    Article  CAS  Google Scholar 

  7. World Health Organisation. 2021 AWaRe classification. Accessed 09 June, 2022. Available from: https://www.who.int/publications/i/item/2021-aware-classification

  8. Critchley IA, Brown SD, Traczewski MM. National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005–2006 U.S. Faropenem surveillance study. Antimicrob Agents Chemother. 2007;51:4382–89.

    Article  CAS  Google Scholar 

  9. Gandra S, Klein EY, Pant S, et al. Faropenem consumption is increasing in india, Clinical Infectious Diseases. 2016;62:1050–2.

    Article  Google Scholar 

  10. Faropenem medoxomil. A0026, BAY 56–6854, BAY 566854, faropenem daloxate, SUN 208, SUN A0026. Drugs R D. 2008; 9:115–24.

    Google Scholar 

  11. European Medicines Agency. Human regulatory. Accessed June 24, 2022. Available from: https://www.ema.europa.eu/en/human-regulatory/post-authorisation/data-medicines-iso-idmpstandards/public-data-article-57-database

  12. Central Drugs Standard Control Organisation. Recommendations of the SEC (Antimicrobial & Antiviral) made in its 103rd meeting held on 25.08.2021 at CDSCO HQ, New Delhi. Accessed on 30 May, 2022. Available from: https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadCom mitteeFiles/Recommendations%20Antimicrobial%20&%20Antiviral%2027.07.2021.pdf

  13. Sanz MG, Marta GS, Vicens D-BF, et al. The elephant in the room: could the unregulated marketing of generic faropenem sodium be contributing to penem overuse? ECCMID 2016; 9 April 2016; Amsterdam, Netherlands.

  14. Gandra S, Klein EY, Pant S, et al. Faropenem consumption is increasing in India. Clin Infect Dis. 2016;62:1050–2.

    Article  Google Scholar 

  15. Global Faropenem Sodium Market Research Report (2021 to 2026) — by Product, Type and Region. Dec 2021. Accessed June 06, 2022. Available from: https://www.globenewswire.com/news-release/2021/12/17/2354499/28124/en/Global-Faropen emSodium-Market-Research-Report-2021-to-2026-by-Product-Type-and-Region.html

  16. Tiberi S, Sanz MG, Millar M. The need for global regulation of antibiotics: The case of a generic oral penem. Clin Infect Dis. 2016;62:1466–7.

    Article  Google Scholar 

  17. Global Essential medicines. India. Accessed July 05, 2022. Available from: https://global.essentialmeds.org/dashboard/countries/56

  18. The Gazette of India: Extraordinary. Schedule H drugs, last amended vide notification number G.s.R. z2 (E), dated the 8th February, 2013, New Delhi. Accessed on 08 June, 2022. Available from: http://www.dcaodisha.nic.in/sites/default/files/Schedule%20H1%20Drugs.pdf

Download references

Author information

Authors and Affiliations

  1. Pediatric Infectious Diseases, Apollo Hospitals, CBD Belapur, Navi Mumbai, Maharashtra, 400 614, India

    Dhanya Dharmapalan

  2. Department of Pharmacology and Clinical Pharmacology, Christian Medical College, Vellore, Tamil Nadu, India

    Sujith J. Chandy

Authors
  1. Dhanya Dharmapalan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sujith J. Chandy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dhanya Dharmapalan.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dharmapalan, D., Chandy, S.J. Oral Faropenem Sodium — Implications for Antimicrobial Resistance and Treatment Effectiveness. Indian Pediatr 59, 879–881 (2022). https://doi.org/10.1007/s13312-022-2648-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13312-022-2648-5

Keywords

Search

Navigation